Terlipressin Hrs denied for missing prior authorization by Humana?

Humana's specific coverage criteria for terlipressin hrs are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Terlipressin — and How to Navigate It

Terlipressin is an FDA-approved treatment for hepatorenal syndrome type 1 (HRS-1). Humana requires prior authorization (PA) before it will cover terlipressin, meaning the prescriber must submit a clinical justification and receive approval before the drug is administered or dispensed. A PA-required denial is not a final clinical determination — it means the authorization process was not completed, was submitted with insufficient information, or was denied for a correctable reason.

### Why This Denial Happens

Humana uses prior authorization to verify that a drug is being used for an approved indication, that clinical criteria are met, and that required prior steps (if any) have been attempted. For a specialty drug like terlipressin — administered in a hospital or infusion setting for a serious acute condition — the PA process can create access delays if the submission is incomplete or if the initial request does not include all the documentation Humana's policy requires.

### Why It's Appealable

A PA denial triggers full appeal rights under ACA §2719 and ERISA §503. You have the right to internal review by a physician not involved in the initial determination, followed by independent external review if the internal appeal is denied. File for external review within approximately four months of the denial notice. For a hospitalized patient with active HRS-1, request expedited review — plans must render a decision within 72 hours when standard timelines would seriously jeopardize health.

### Concrete Appeal Process

1. Determine the denial basis — Request the specific PA criteria Humana applied and the precise reason for denial (missing documentation, unmet criterion, required step not documented). 2. Supplement the record — Gather the missing documentation (see below) and resubmit as an appeal, not just a new PA request. 3. Internal appeal — File within the deadline on the denial letter with a complete clinical package and a prescriber letter. 4. Expedited review — For inpatient HRS-1, the prescriber should certify urgency in writing when requesting expedited handling. 5. External review — Available after an adverse internal decision; particularly effective when the denial was based on an incomplete record rather than a genuine clinical disagreement.

### Documentation to Gather

• Diagnosis confirmation — hepatologist or intensivist chart notes documenting the HRS-1 diagnosis consistent with the criteria in the FDA-approved prescribing information.
• Prior-treatment history — records of any prior agents Humana's PA criteria require, with dates, outcomes, and documented reasons for inadequacy.
• Clinical severity — objective clinical and laboratory findings from the chart reflecting current disease status and urgency.
• Prescriber medical-necessity letter — a detailed letter from the treating physician addressing each of Humana's PA criteria one by one and citing the applicable professional society guideline (such as AASLD guidance on HRS).

### Criteria-Mapping Structure

Obtain Humana's published PA criteria for terlipressin and the FDA prescribing label. Create a table with each PA requirement in the left column and the corresponding chart documentation in the right column, with the date and source document for each entry. A complete criteria map submitted with the appeal eliminates the most common reason PA appeals fail — the reviewer cannot find the supporting documentation quickly enough to approve.